Jump to navigation
From the development of treatments for illnesses without an accepted treatment to the creation of new superfoods, the legal cannabis industry continues to make incredible strides forward.
The last month has been significant for the global cannabis industry and recent developments have left us even more bullish on certain sub-industries as well as companies.
Cannabis is Going Global
Although the Nasdaq traded at a new all-time high and was the top performing exchange yesterday, biotech stocks moved lower as the iShares Nasdaq Biotechnology ETF (IBB) fell less than 1%.
Despite the post-election rally, the biotech sector has been under pressure due to President Trump’s comments pertaining to lowering drug prices. Although we expect to see several biotech companies negatively impacted by future changes in pricing, many companies will not be affected.
Last week, the global cannabis movement took one step forward after Germany's lower house of parliament passed legislation to legalize medical cannabis for people suffering from debilitating illnesses.
Under the new law, people suffering from serious illnesses such as multiple sclerosis, chronic pain, or a lack of appetite and nausea could access medical cannabis.
From the National Cancer Institute (NCI) to the National Institute on Drug Abuse (NIDA), U.S. government agencies continue to change its stance pertaining to medical cannabis.
Last year, the NCI updated its website to include various studies that reveal how cannabis may inhibit tumor growth by killing cells. The NIDA revised their April 2015 publication to say that marijuana can kill certain cancer cells and reduce the size of others.
The stock market reacted in a volatile manner to President-elect Donald Trump’s first press conference since the election.
Cannabis stocks were not immune from this volatility and we are closely monitoring biotech stocks levered to the cannabis industry as yesterday’s trading activity was not like anything we have seen before.
An Unprecedented Reaction
Is Germany the major growth frontier for the medical cannabis industry?
Many news outlets have recently discussed the potential opening of cannabis coffee shops in Germany and this has left investors wondering how this may impact their investments, specifically Canopy Growth Corp (CGC.TO) (TWMJF).
As the cannabis industry continues to expand, new opportunities continue to emerge.
From private placements to publicly traded companies, there are a number of avenues available for potential and current cannabis investors. Given the nature of the industry, though, many or do not understand or are aware of these opportunities.
Cannabis stocks ended the year on a high note and 2016 was a great year for the cannabis industry. From Canada to Australia, the United States to Germany, the global cannabis industry continued to expand and the stage is set for further growth in 2017.
Although the cannabis sector saw a turnaround in 2016, the sector really started to rally in late August and we want to highlight 11 cannabis stocks that investors should watch during 2017.
Will Canadian cannabis stocks remain under pressure following the release of information related to product recalls or will this weakness provide investors with the best buying opportunity of 2017?
Late last week, The Globe and Mail published an article on the discovery of Myclobutanil, a controversial pesticide found in in products sold by Mettrum Ltd. (MT.V), a federally licensed medical cannabis producer.
What is Myclobutanil?
These opportunities do not come around every day... be one of the first to learn about five investments that are flying under the radar!
Ten years from now, we will be able to look back at what happened in the cannabis industry during 2016 and understand the significance of this time period in the history of cannabis.
Processing, please wait. This may take up to 15 seconds to complete.
Please do not close your browser.